Division of Pediatric Emergency and Critical Care, Department of Pediatrics, Advanced Pediatrics Center, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012, India.
Indian J Pediatr. 2023 Apr;90(4):334-340. doi: 10.1007/s12098-022-04271-4. Epub 2022 Jul 8.
To describe the clinical and laboratory profile, management, intensive care needs, and outcome of children with toxic shock syndrome (TSS) admitted to the pediatric intensive care unit (PICU) of a tertiary care center in North India.
This retrospective study was conducted in the PICU of a tertiary care hospital in North India over a period of 10 y (January 2011-December 2020) including children < 12 y with TSS (n = 63).
The median (interquartile range, IQR) age was 5 (2-9) y, 58.7% were boys, and Pediatric Risk of Mortality III (PRISM-III) score was 15 (12-17). The primary focus of infection was identified in 60.3% children, 44.5% had skin and soft tissue infections, and 17.5% (n = 11) had growth of Staphylococcus aureus. Common manifestations were shock (100%), rash (95.2%), thrombocytopenia (79.4%), transaminitis (66.7%), coagulopathy (58.7%), and acute kidney injury (AKI) (52.4%); and involvement of gastrointestinal (61.9%), mucus membrane (55.5%), respiratory (47.6%), musculoskeletal (41.3%), and central nervous system (CNS) (31.7%). The treatment included fluid resuscitation (100%), vasoactive drugs (92.1%), clindamycin (96.8%), intravenous immunoglobulin (IVIG) (92.1%), blood products (74.6%), mechanical ventilation (58.7%), and renal replacement therapy (31.7%). The mortality was 27% (n = 17). The duration of PICU and hopsital stay was 5 (4-10) and 7 (4-11) d, respectively. Higher proportion of nonsurvivors had CNS involvement, transaminitis, thrombocytopenia, coagulopathy, and AKI; required mechanical ventilation and blood products; and had higher vasoactive-inotropic score.
TSS is not uncommon in children in Indian setup. The management includes early recognition, intensive care, antibiotics, source control, and adjunctive therapy (IVIG and clindamycin). Multiorgan dysfunction and need for organ supportive therapies predicted mortality.
描述印度北部一家三级保健中心儿科重症监护病房(PICU)收治的中毒性休克综合征(TSS)患儿的临床和实验室特征、治疗、重症监护需求和结局。
本回顾性研究纳入了印度北部一家三级医院 PICU 在 10 年间(2011 年 1 月至 2020 年 12 月)收治的 < 12 岁 TSS 患儿(n = 63)。
患儿的中位(四分位距,IQR)年龄为 5(2-9)岁,58.7%为男孩,儿科危重病评分-3 (PRISM-3)评分为 15(12-17)。60.3%患儿的感染原明确,44.5%有皮肤和软组织感染,17.5%(n = 11)检出金黄色葡萄球菌生长。常见表现为休克(100%)、皮疹(95.2%)、血小板减少症(79.4%)、肝转氨酶升高(66.7%)、凝血功能障碍(58.7%)和急性肾损伤(AKI)(52.4%);胃肠道受累(61.9%)、黏膜受累(55.5%)、呼吸系统受累(47.6%)、肌肉骨骼系统受累(41.3%)和中枢神经系统(CNS)受累(31.7%)。治疗包括液体复苏(100%)、血管活性药物(92.1%)、克林霉素(96.8%)、静脉用免疫球蛋白(IVIG)(92.1%)、血制品(74.6%)、机械通气(58.7%)和肾脏替代治疗(31.7%)。死亡率为 27%(n = 17)。患儿 PICU 住院时间和总住院时间分别为 5(4-10)和 7(4-11)d。死亡组患儿更易发生 CNS 受累、肝转氨酶升高、血小板减少症、凝血功能障碍和 AKI,需要机械通气和血制品,血管活性-正性肌力评分更高。
印度儿童中 TSS 并不少见。其治疗包括早期识别、重症监护、抗生素治疗、源头控制和辅助治疗(IVIG 和克林霉素)。多器官功能障碍和器官支持治疗的需求预测了死亡率。